| Aug 1 |
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
|
| Jul 16 |
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
|
| Jul 16 |
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
|
| Jun 26 |
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
|
| Jun 13 |
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability
|
| Jun 5 |
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
|
| May 23 |
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate
|
| May 23 |
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
|
